Eosinophilic Granulomatosis with Polyangiitis Treatment and Forecast Market
1 Introduction to Research & Analysis Reports
1.1 Eosinophilic Granulomatosis with Polyangiitis Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Overall Market Size
2.1 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size: 2023 VS 2030
2.2 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, Prospects & Forecasts: 2019-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players in Global Market
3.2 Top Global Eosinophilic Granulomatosis with Polyangiitis Treatment Companies Ranked by Revenue
3.3 Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue by Companies
3.4 Top 3 and Top 5 Eosinophilic Granulomatosis with Polyangiitis Treatment Companies in Global Market, by Revenue in 2023
3.5 Global Companies Eosinophilic Granulomatosis with Polyangiitis Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Eosinophilic Granulomatosis with Polyangiitis Treatment Players in Global Market
3.6.1 List of Global Tier 1 Eosinophilic Granulomatosis with Polyangiitis Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Eosinophilic Granulomatosis with Polyangiitis Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size Markets, 2023 & 2030
4.1.2 Steroids
4.1.3 Immunosuppressant
4.1.4 Biologics
4.1.5 Immune Globulins
4.2 By Type - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue & Forecasts
4.2.1 By Type - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, 2019-2024
4.2.2 By Type - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, 2025-2030
4.2.3 By Type - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2023 & 2030
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue & Forecasts
5.2.1 By Application - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, 2019-2024
5.2.2 By Application - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, 2025-2030
5.2.3 By Application - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
6 Sights by Region
6.1 By Region - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2023 & 2030
6.2 By Region - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue & Forecasts
6.2.1 By Region - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, 2019-2024
6.2.2 By Region - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, 2025-2030
6.2.3 By Region - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
6.3 North America
6.3.1 By Country - North America Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, 2019-2030
6.3.2 US Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.3.3 Canada Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.3.4 Mexico Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.4 Europe
6.4.1 By Country - Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, 2019-2030
6.4.2 Germany Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.4.3 France Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.4.4 U.K. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.4.5 Italy Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.4.6 Russia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.4.7 Nordic Countries Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.4.8 Benelux Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.5 Asia
6.5.1 By Region - Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, 2019-2030
6.5.2 China Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.5.3 Japan Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.5.4 South Korea Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.5.5 Southeast Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.5.6 India Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.6 South America
6.6.1 By Country - South America Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, 2019-2030
6.6.2 Brazil Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.6.3 Argentina Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, 2019-2030
6.7.2 Turkey Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.7.3 Israel Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.7.4 Saudi Arabia Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
6.7.5 UAE Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size, 2019-2030
7 Eosinophilic Granulomatosis with Polyangiitis Treatment Companies Profiles
7.1 Teva Pharmaceutical Industries
7.1.1 Teva Pharmaceutical Industries Company Summary
7.1.2 Teva Pharmaceutical Industries Business Overview
7.1.3 Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Major Product Offerings
7.1.4 Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global Market (2019-2024)
7.1.5 Teva Pharmaceutical Industries Key News & Latest Developments
7.2 GlaxoSmithKline
7.2.1 GlaxoSmithKline Company Summary
7.2.2 GlaxoSmithKline Business Overview
7.2.3 GlaxoSmithKline Eosinophilic Granulomatosis with Polyangiitis Treatment Major Product Offerings
7.2.4 GlaxoSmithKline Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global Market (2019-2024)
7.2.5 GlaxoSmithKline Key News & Latest Developments
7.3 Genentech
7.3.1 Genentech Company Summary
7.3.2 Genentech Business Overview
7.3.3 Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Major Product Offerings
7.3.4 Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global Market (2019-2024)
7.3.5 Genentech Key News & Latest Developments
7.4 Baxter Healthcare
7.4.1 Baxter Healthcare Company Summary
7.4.2 Baxter Healthcare Business Overview
7.4.3 Baxter Healthcare Eosinophilic Granulomatosis with Polyangiitis Treatment Major Product Offerings
7.4.4 Baxter Healthcare Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global Market (2019-2024)
7.4.5 Baxter Healthcare Key News & Latest Developments
7.5 F. Hoffmann-La Roche
7.5.1 F. Hoffmann-La Roche Company Summary
7.5.2 F. Hoffmann-La Roche Business Overview
7.5.3 F. Hoffmann-La Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Major Product Offerings
7.5.4 F. Hoffmann-La Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global Market (2019-2024)
7.5.5 F. Hoffmann-La Roche Key News & Latest Developments
7.6 Cephalon
7.6.1 Cephalon Company Summary
7.6.2 Cephalon Business Overview
7.6.3 Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Major Product Offerings
7.6.4 Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global Market (2019-2024)
7.6.5 Cephalon Key News & Latest Developments
7.7 Amgen
7.7.1 Amgen Company Summary
7.7.2 Amgen Business Overview
7.7.3 Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Major Product Offerings
7.7.4 Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global Market (2019-2024)
7.7.5 Amgen Key News & Latest Developments
7.8 Sanofi S.A.
7.8.1 Sanofi S.A. Company Summary
7.8.2 Sanofi S.A. Business Overview
7.8.3 Sanofi S.A. Eosinophilic Granulomatosis with Polyangiitis Treatment Major Product Offerings
7.8.4 Sanofi S.A. Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global Market (2019-2024)
7.8.5 Sanofi S.A. Key News & Latest Developments
7.9 Koninklijke DSM N.V
7.9.1 Koninklijke DSM N.V Company Summary
7.9.2 Koninklijke DSM N.V Business Overview
7.9.3 Koninklijke DSM N.V Eosinophilic Granulomatosis with Polyangiitis Treatment Major Product Offerings
7.9.4 Koninklijke DSM N.V Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global Market (2019-2024)
7.9.5 Koninklijke DSM N.V Key News & Latest Developments
7.10 AstraZeneca
7.10.1 AstraZeneca Company Summary
7.10.2 AstraZeneca Business Overview
7.10.3 AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Major Product Offerings
7.10.4 AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global Market (2019-2024)
7.10.5 AstraZeneca Key News & Latest Developments
7.11 Novartis International AG
7.11.1 Novartis International AG Company Summary
7.11.2 Novartis International AG Business Overview
7.11.3 Novartis International AG Eosinophilic Granulomatosis with Polyangiitis Treatment Major Product Offerings
7.11.4 Novartis International AG Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global Market (2019-2024)
7.11.5 Novartis International AG Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
List of Tables
Table 1. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Opportunities & Trends in Global Market
Table 2. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Drivers in Global Market
Table 3. Eosinophilic Granulomatosis with Polyangiitis Treatment Market Restraints in Global Market
Table 4. Key Players of Eosinophilic Granulomatosis with Polyangiitis Treatment in Global Market
Table 5. Top Eosinophilic Granulomatosis with Polyangiitis Treatment Players in Global Market, Ranking by Revenue (2023)
Table 6. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue by Companies, (US$, Mn), 2019-2024
Table 7. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Share by Companies, 2019-2024
Table 8. Global Companies Eosinophilic Granulomatosis with Polyangiitis Treatment Product Type
Table 9. List of Global Tier 1 Eosinophilic Granulomatosis with Polyangiitis Treatment Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Eosinophilic Granulomatosis with Polyangiitis Treatment Companies, Revenue (US$, Mn) in 2023 and Market Share
Table 11. By Type ? Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2023 & 2030
Table 12. By Type - Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global (US$, Mn), 2019-2024
Table 13. By Type - Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global (US$, Mn), 2025-2030
Table 14. By Application ? Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2023 & 2030
Table 15. By Application - Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global (US$, Mn), 2019-2024
Table 16. By Application - Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in Global (US$, Mn), 2025-2030
Table 17. By Region ? Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2023 & 2030
Table 18. By Region - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn), 2019-2024
Table 19. By Region - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn), 2025-2030
Table 20. By Country - North America Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2024
Table 21. By Country - North America Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2025-2030
Table 22. By Country - Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2024
Table 23. By Country - Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2025-2030
Table 24. By Region - Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2024
Table 25. By Region - Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2025-2030
Table 26. By Country - South America Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2024
Table 27. By Country - South America Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2025-2030
Table 28. By Country - Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2024
Table 29. By Country - Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2025-2030
Table 30. Teva Pharmaceutical Industries Company Summary
Table 31. Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offerings
Table 32. Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn) & (2019-2024)
Table 33. Teva Pharmaceutical Industries Key News & Latest Developments
Table 34. GlaxoSmithKline Company Summary
Table 35. GlaxoSmithKline Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offerings
Table 36. GlaxoSmithKline Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn) & (2019-2024)
Table 37. GlaxoSmithKline Key News & Latest Developments
Table 38. Genentech Company Summary
Table 39. Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offerings
Table 40. Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn) & (2019-2024)
Table 41. Genentech Key News & Latest Developments
Table 42. Baxter Healthcare Company Summary
Table 43. Baxter Healthcare Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offerings
Table 44. Baxter Healthcare Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn) & (2019-2024)
Table 45. Baxter Healthcare Key News & Latest Developments
Table 46. F. Hoffmann-La Roche Company Summary
Table 47. F. Hoffmann-La Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offerings
Table 48. F. Hoffmann-La Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn) & (2019-2024)
Table 49. F. Hoffmann-La Roche Key News & Latest Developments
Table 50. Cephalon Company Summary
Table 51. Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offerings
Table 52. Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn) & (2019-2024)
Table 53. Cephalon Key News & Latest Developments
Table 54. Amgen Company Summary
Table 55. Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offerings
Table 56. Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn) & (2019-2024)
Table 57. Amgen Key News & Latest Developments
Table 58. Sanofi S.A. Company Summary
Table 59. Sanofi S.A. Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offerings
Table 60. Sanofi S.A. Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn) & (2019-2024)
Table 61. Sanofi S.A. Key News & Latest Developments
Table 62. Koninklijke DSM N.V Company Summary
Table 63. Koninklijke DSM N.V Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offerings
Table 64. Koninklijke DSM N.V Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn) & (2019-2024)
Table 65. Koninklijke DSM N.V Key News & Latest Developments
Table 66. AstraZeneca Company Summary
Table 67. AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offerings
Table 68. AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn) & (2019-2024)
Table 69. AstraZeneca Key News & Latest Developments
Table 70. Novartis International AG Company Summary
Table 71. Novartis International AG Eosinophilic Granulomatosis with Polyangiitis Treatment Product Offerings
Table 72. Novartis International AG Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue (US$, Mn) & (2019-2024)
Table 73. Novartis International AG Key News & Latest Developments
List of Figures
Figure 1. Eosinophilic Granulomatosis with Polyangiitis Treatment Segment by Type in 2023
Figure 2. Eosinophilic Granulomatosis with Polyangiitis Treatment Segment by Application in 2023
Figure 3. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Overview: 2023
Figure 4. Key Caveats
Figure 5. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Market Size: 2023 VS 2030 (US$, Mn)
Figure 6. Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, 2019-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue in 2023
Figure 8. By Type - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
Figure 9. By Application - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
Figure 10. By Type - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2023 & 2030
Figure 11. By Type - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
Figure 12. By Application - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2023 & 2030
Figure 13. By Application - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
Figure 14. By Region - Global Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
Figure 15. By Country - North America Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
Figure 16. US Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 17. Canada Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 18. Mexico Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 19. By Country - Europe Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
Figure 20. Germany Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 21. France Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 22. U.K. Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 23. Italy Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 24. Russia Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 25. Nordic Countries Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 26. Benelux Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 27. By Region - Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
Figure 28. China Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 29. Japan Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 30. South Korea Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 31. Southeast Asia Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 32. India Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 33. By Country - South America Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
Figure 34. Brazil Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 35. Argentina Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 36. By Country - Middle East & Africa Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Market Share, 2019-2030
Figure 37. Turkey Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 38. Israel Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 39. Saudi Arabia Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 40. UAE Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue, (US$, Mn), 2019-2030
Figure 41. Teva Pharmaceutical Industries Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 42. GlaxoSmithKline Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 43. Genentech Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 44. Baxter Healthcare Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 45. F. Hoffmann-La Roche Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 46. Cephalon Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 47. Amgen Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 48. Sanofi S.A. Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 49. Koninklijke DSM N.V Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 50. AstraZeneca Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
Figure 51. Novartis International AG Eosinophilic Granulomatosis with Polyangiitis Treatment Revenue Year Over Year Growth (US$, Mn) & (2019-2024)
